A secondary analysis of the EVEREST trial found that adjuvant everolimus did not provide a recurrence-free or overall survival benefit in patients with localized non–clear cell RCC.

Meeting Coverage > SABCS Everolimus Fails Again as Adjuvant Therapy for High-Risk Breast Cancer — No improvement in the overall analysis but a hint of benefit in premenopausal patients ...

S0931 is funded by the NIH/NCI through grants U10CA180888, U10CA180819, U10CA180820, and U10CA180821 and is supported in part by Novartis Pharmaceuticals Corporation.

Adjuvant everolimus lowers the risk for cancer recurrence in patients with completely resected, very high-risk clear cell renal cell carcinoma (RCC), a new study finds. But there is no overall ...

Our study's safety and efficacy results for everolimus in recurrent/progressive pLGGs (PNOC001) align with a smaller phase II trial that found everolimus to be well tolerated. 23,33 The PFS rates in ...

PURPOSEPhosphatidylinositol 3-kinase/AKT-serine threonine kinase/mammalian target of rapamycin (mTOR) pathway abnormalities contribute to endocrine resistance. Everolimus, an mTOR inhibitor, improved ...

According to IQVIA ®, U.S. annual sales for memantine/donepezil tablets, everolimus tablets and rifaximin tablets for the 12 months ended November 2024 were approximately $88 million, $114 ...

Everolimus tablets for oral suspension (TFOS), 2mg, 3mg and 5mg, had estimated sales of USD 112 million in the US for 12 months ending Sep'24 as per industry sales data, Natco said.